Overview

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

Status:
Terminated

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.

Phase:

Phase 4

Details

Lead Sponsor:

Galderma Laboratories, L.P.

Treatments:

Fluocinolone Acetonide
Hydroquinone
Tretinoin